Acurx Pharmaceuticals Q3 net loss widens 30% to $2.58 million
ACXP•Acurx Pharmaceuticals’ third-quarter 2026 net loss widened 30% year over year to $2.58 million. Cash was $9.65 million at September 30, and enrollment began in its 20-patient PATHFINDER trial on September 29.
1. Quarterly results and trial
Acurx Pharmaceuticals’ third-quarter 2026 net loss widened 30% year over year to $2.58 million. Research and development expenses more than doubled to $1.12 million, primarily due to higher consulting costs for the recurrent CDI trial program. Cash totaled $9.65 million at September 30, up 28% from December 31, 2025. Enrollment began September 29 in the fully funded, 20-patient PATHFINDER trial of ibezapolstat in multiply recurrent CDI.
